PMID: 8438903Mar 1, 1993

Comparison of acute myeloid leukemia occurring de novo or preceded by a myelodysplastic stage: differences in cellular DNA content

American Journal of Hematology
S WidellP Reizenstein


The DNA content of bone marrow cells in patients with acute leukemia preceded by a myelodysplastic stage (MDS-AML) was compared to that in patients with de novo AML. We studied granulocytes, lymphocytes, monocytes, and blasts/promyelocytes from Feulgen-stained bone marrow smears of 11 patients with de novo AML, ten patients with MDS-AML, and 13 apparently healthy controls. The mean amount of DNA per cell (DNA index; DI) in each cell population was determined using a digital video-based image-analyzing system (CAS-100). Analysis of variance (F test) showed a significant difference in the DNA content between de novo AML on one hand and MDS-AML and controls on the other as regards to blasts/promyelocytes (P < 0.01), lymphocytes (P < 0.05), and monocytes (P < 0.01), respectively. In three of 11 (27%) patients with de novo AML, a lower than normal limit DI was found both in immature and mature bone marrow cells. Patients with MDS-AML had those of DI values similar to normal controls. In consequence, a significantly reduced mean DI was found in patients with de novo AML in blasts/promyelocytes (P < 0.01), and monocytes (P < 0.05) compared to both normal controls and MDS-AML. Together with data published separately, suggesting differe...Continue Reading


Mar 1, 1990·American Journal of Clinical Pathology·T W BauerH S Levin
Jun 1, 1989·Human Pathology·G AuerO Ahrens
May 1, 1989·Journal of Clinical Pathology·T G HoyA Jacobs
Jan 1, 1989·Leukemia Research·V Maitreyan, R E Gale
Jan 1, 1985·Acta Haematologica·P ReizensteinA Porwit
Jan 1, 1988·Leukemia Research·R S VermaM Coleman
Jun 1, 1988·Journal of Clinical Pathology·W AuffermannA Böcking
Oct 1, 1987·Cancer Genetics and Cytogenetics·B BarlogieEmil Freireich
Aug 20, 1987·The New England Journal of Medicine·P J FialkowR Veith
Jun 5, 1986·The New England Journal of Medicine·R E ClarkA Jacobs
Nov 1, 1986·Archives of Ophthalmology·W J Meecham, D H Char
Oct 1, 1984·Cancer Genetics and Cytogenetics·W HiddemannA A Sandberg
Jan 1, 1982·Medical and Pediatric Oncology·G A HoeltgeM L Slovak
Jun 5, 1962·Annals of the New York Academy of Sciences·T O CASPERSSON, G M LOMAKKA
Aug 15, 1987·Applied Optics·J W Bacus, L J Grace


Nov 11, 1999·British Journal of Haematology·S WidellJ M Bennett
Aug 1, 1993·American Journal of Hematology·S WidellP Reizenstein

Related Concepts

Bone Marrow Cells
DNA, Neoplasm
Acute Monocytic Leukemia
Hematopoetic Myelodysplasia
Reproducibility of Results
Acute Myeloid Leukemia, M1
Acute Myelomonocytic Leukemia

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.